FDA Approval Summary: Ruxolitinib for Treatment of Chronic Graft-Versus-Host Disease after Failure of One or Two Lines of Systemic Therapy.

Autor:	Le RQ; Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD, USA., Wang X; Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD, USA., Zhang H; Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD, USA., Li H; Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD, USA., Przepiorka D; Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD, USA., Vallejo J; Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD, USA., Leong R; Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD, USA., Ma L; Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD, USA., Goldberg KB; Oncology Center of Excellence, U.S. Food and Drug Administration, Silver Spring, MD, USA., Pazdur R; Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD, USA.; Oncology Center of Excellence, U.S. Food and Drug Administration, Silver Spring, MD, USA., Theoret MR; Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD, USA.; Oncology Center of Excellence, U.S. Food and Drug Administration, Silver Spring, MD, USA., De Claro A; Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD, USA.
Jazyk:	angličtina
Zdroj:	The oncologist [Oncologist] 2022 Jun 08; Vol. 27 (6), pp. 493-500.
DOI:	10.1093/oncolo/oyac042
Abstrakt:	On September 22, 2021, the Food and Drug Administration approved ruxolitinib for the treatment of chronic graft-versus-host disease (cGVHD) after the failure of one or two lines of systemic therapy in adult and pediatric patients 12 years and older. Approval was based on Study INCB 18424-365 (REACH-3; CINC424D2301; NCT03112603), a randomized, open-label, multicenter trial of ruxolitinib in comparison to best available therapy (BAT) for the treatment of corticosteroid-refractory cGVHD occurring after the allogeneic hematopoietic stem cell transplantation. A total of 329 patients were randomized 1:1 to receive either ruxolitinib 10 mg twice daily (n = 165) or BAT (n = 164). BAT was selected by the investigator prior to randomization. The overall response rate through Cycle 7 Day 1 was 70% (95% CI, 63-77) in the ruxolitinib arm, and 57% (95% CI, 49-65) in the BAT arm. The median duration of response, calculated from first response to progression, death, or initiation of new systemic therapies for cGVHD, was 4.2 months (95% CI, 3.2-6.7) for the ruxolitinib arm and 2.1 months (95% CI, 1.6-3.2) for the BAT arm; and the median time from first response to death or initiation of new systemic therapies for cGVHD was 25 months (95% CI, 16.8-not estimable) for the ruxolitinib arm and 5.6 months (95% CI, 4.1-7.8) for the BAT arm. Common adverse reactions included anemia, thrombocytopenia, and infections. Given the observed response rate with durability, the clinical benefit of ruxolitinib appears to outweigh the risks of treatment for cGVHD after the failure of one or two lines of systemic therapy. (Published by Oxford University Press 2022.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu